Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C F Verschraegen

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
Current Treatment Options in Oncology|June 12, 2002
Intracavitary therapies for mesotheliomaC F Verschraegen
Current Opinion in Investigational Drugs (London, England : 2000)|January 5, 2002
ET-743 (PharmaMar/NCI/Ortho Biotech)C F Verschraegen, K Glover
Tumori|February 28, 1994
Medical management of colorectal carcinomasC F Verschraegen, R Pazdur
Hematology/Oncology Clinics of North America|March 18, 1999
Topoisomerase-I inhibitors in gynecologic tumorsP Haluska, E Rubin, C F Verschraegen
Hematology/Oncology Clinics of North America|March 18, 1999
Present knowledge of gynecologic sarcoma managementC F Verschraegen, C L Edwards, H Fox
The New England Journal of Medicine|April 4, 1998
Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470A P Kudelka, C F Verschraegen, E Loyer
Annals of the Academy of Medicine, Singapore|January 27, 1999
Topoisomerase-I inhibitors in gynaecologic tumoursC F Verschraegen, A P Kudelka, J J Kavanagh
Oncology (Williston Park, N.Y.)|September 3, 1998
Irinotecan in cervical cancerJ J Kavanagh, C F Verschraegen, A P Kudelka
Current Opinion in Obstetrics & Gynecology|February 1, 1997
Taxanes in ovarian cancer treatmentK Seetalarom, A P Kudelka, C F Verschraegen, et al.
Annals of the New York Academy of Sciences|February 24, 2001
Alternative administration of camptothecin analoguesC F Verschraegen, K Jaeckle, B Giovanella, et al.
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
Current Treatment Options in Oncology|June 12, 2002
Intracavitary therapies for mesotheliomaC F Verschraegen
Current Opinion in Investigational Drugs (London, England : 2000)|January 5, 2002
ET-743 (PharmaMar/NCI/Ortho Biotech)C F Verschraegen, K Glover
Tumori|February 28, 1994
Medical management of colorectal carcinomasC F Verschraegen, R Pazdur
Hematology/Oncology Clinics of North America|March 18, 1999
Topoisomerase-I inhibitors in gynecologic tumorsP Haluska, E Rubin, C F Verschraegen
Hematology/Oncology Clinics of North America|March 18, 1999
Present knowledge of gynecologic sarcoma managementC F Verschraegen, C L Edwards, H Fox
The New England Journal of Medicine|April 4, 1998
Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470A P Kudelka, C F Verschraegen, E Loyer
Annals of the Academy of Medicine, Singapore|January 27, 1999
Topoisomerase-I inhibitors in gynaecologic tumoursC F Verschraegen, A P Kudelka, J J Kavanagh
Oncology (Williston Park, N.Y.)|September 3, 1998
Irinotecan in cervical cancerJ J Kavanagh, C F Verschraegen, A P Kudelka
Current Opinion in Obstetrics & Gynecology|February 1, 1997
Taxanes in ovarian cancer treatmentK Seetalarom, A P Kudelka, C F Verschraegen, et al.
Annals of the New York Academy of Sciences|February 24, 2001
Alternative administration of camptothecin analoguesC F Verschraegen, K Jaeckle, B Giovanella, et al.
Pageof 7